Incidence and treatment of infantile haemangioma in preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 100, Issue 1, 2015, Pages F85-F91

  Goelz, Rangmar ^a   Poets, Christian F ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; NITROGEN; PROPRANOLOL; STEROID; TIMOLOL MALEATE; VINCRISTINE; TIMOLOL;

BIRTH WEIGHT; CAPILLARY HEMANGIOMA; CAUCASIAN; CRYOTHERAPY; DISEASE ASSOCIATION; DRUG EFFECT; FACE DISORDER; GESTATIONAL AGE; HUMAN; INCIDENCE; INFANT; LOW LEVEL LASER THERAPY; NITROGEN COOLED CRYOCONTACT THERAPY; PREMATURITY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SYSTEMIC THERAPY; TERM BIRTH; TOPICAL TREATMENT; TREATMENT INDICATION; VERY LOW BIRTH WEIGHT; HEMANGIOMA; INFANT, PREMATURE, DISEASES; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CRYOTHERAPY; HEMANGIOMA; HUMANS; INCIDENCE; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PROPRANOLOL; TIMOLOL; TREATMENT OUTCOME;

EID: 84919884367     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306197     Document Type: Review

References (73)

1. Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics 2012;130:e314-20.
2. Bruckner AL, Frieden IJ. Infantile hemangiomas. J Am Acad Dermatol 2006;55:671-82.
3. Haggstrom AN, Lammer EJ, Schneider RA, et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006;117:698-703.
4. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008;122:360-7.
5. Luu M, Frieden IJ. Haemangioma: clinical course, complications and management. Br J Dermatol 2013;169:20-30.
6. Couto RA, Maclellan RA, Zurakowski D, et al. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg 2012;130:619-24.
7. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classi fication based on endothelial characteristics. Plast Reconstr Surg 1982;69:412-22.
8. Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg 1983;18:894-900.
9. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008;25:168-73.
10. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006;118:882-7.
11. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002;138:1567-76.
12. Leaute-Labreze C, Prey S, Ezzedine K. Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol 2011;25:1245-53.
13. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999;341:173-81.
14. Puttgen KB. Diagnosis and management of infantile hemangiomas. Pediatr Clin North Am 2014;61:383-402.
15. North PE, Mizeracki A, Mihm MC Jr, et al. GLUT1 immunoreaction patterns reliably distinguish hemangioblastoma from metastatic renal cell carcinoma. Clin Neuropathol 2000;19:131-7.
16. Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics 2013;131:99-108.
17. Funk T, Prok L, Brown LD, et al. Multifocal vascular tumors and fetal hydrops. J Pediatr 2014;164:1214-18.
18. Mulliken JB, Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 2004;50:875-82.
19. Haggstrom AN, Drolet BA, Baselga E, et al. Hemangioma Investigator Group. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291-4.
20. Kanada KN, Merin MR, Munden A, et al . A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012;161:240-5.
21. Sidoroff A. [Epidemiology of cutaneous vascular neoplasms and malformations in childhood]. Handchir Mikrochir Plast Chir 2009;41:65-9.
22. Garzon MC, Drolet BA, Baselga E, et al. Comparison of infantile hemangiomas in preterm and term infants: a prospective study. Arch Dermatol 2008;144:1231-2.
23. Holmdahl K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr 1955;44:370-9.
24. Powell TG, West CR, Pharoah PO, et al. Epidemiology of strawberry haemangioma in low birthweight infants. Br J Dermatol 1987;116:635-41.
25. Amir J, Metzker A, Krikler R, et al. Strawberry hemangioma in preterm infants. Pediatr Dermatol 1986;3:331-2.
26. Queisser-Luft A, Schlaefer K, Schicketanz KH, et al. Erfassung angeborener Fehlbildungen bei Neugeborenen: Das Mainzer Modell. Dtsch Ärzteblatt 1987;91: A-747-50.
27. Praveen V, Vidavalur R, Rosenkrantz TS, et al. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics 2009;123:e484-9.
28. Dickison P, Christou E, Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol 2011;28:663-9.
29. Doege C, Pritsch M, Fruhwald MC, et al. An association between infantile haemangiomas and erythropoietin treatment in preterm infants. Arch Dis Child Fetal Neonatal Ed 2012;97:F45-9.
30. Goelz R, Moll M, Meisner C, et al. Prospective controlled study to evaluate cryocontact therapy for infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2014;99:F345-6.
31. Leonardi-Bee J, Batta K, O'Brien C, et al. Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database Syst Rev 2011(5): CD006545.
32. Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007;151:684-9, 9.e1.
33. Shin HT, Orlow SJ, Chang MW. Ulcerated haemangioma of infancy: a retrospective review of 47 patients. Br J Dermatol 2007;156:1050-2.
34. Grantzow R, Schmittenbecher P, Cremer H, et al. Hemangiomas in infancy and childhood. S 2k Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine. J Deutsch Dermatol Ges 2008;6:324-9.
35. Drolet BA, Swanson EA, Frieden IJ, et al. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008;153:712-15, 5.e1.
36. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013;131:128-40.
37. Bauland CG, Luning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011;127:1643-8.
38. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
39. Gomulka J, Siegel DH, Drolet BA. Dramatic shift in the infantile hemangioma treatment paradigm at a single institution. Pediatr Dermatol 2013;30:751-2.
40. Dreyfus I, Maza A, Mazereeuw-Hautier J. [What's new about infantile hemangiomas?]. Arch Pediatr 2013;20:809-16.
41. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010;128:255-6.
42. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132(3 Pt 1):527-30.
43. Greinwald JH Jr, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999;125:21-7.
44. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:289-96.
45. Abarzua-Araya A, Navarrete-Dechent CP, Heusser F, et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol 2014;70:1045-9.
46. Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2014;140:323-30.
47. Malik MA, Menon P, Rao KL, et al. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg 2013;48:2453-9.
48. Zaher H, Rasheed H, Esmat S, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol 2013;23:646-52.
49. Chan H, McKay C, Adams S, et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013;131:e1739-47.
50. Leaute-Labreze C, Dumas de la Roque E, Nacka F, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants <4 months of age. Br J Dermatol 2013;169:181-3.
51. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011;128:e259-66.
52. Cremer H. Cryosurgery for hemangiomas. Pediatr Dermatol 1998;15:410-11.
53. Bassukas ID, Abuzahra F, Hundeiker M. [Regression phase as therapeutic goal of cryosurgical treatment of growing capillary infantile hemangiomas. Treatment decision, treatment strategy and results of an open clinical study]. Hautarzt 2000;51:231-8.
54. Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet 2002;360:521-7.
55. Hohenleutner U, Landthaler M. Laser treatment of childhood haemangioma: progress or not? Lancet 2002;360:502-3.
56. Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol 2013;30:182-91.
57. Izadpanah A, Izadpanah A, Kanevsky J, et al. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg 2013;131:601-13.
58. Erbay A, Sarialioglu F, Malbora B, et al. Propranolol for infantile hemangiomas: a preliminary report on effi cacy and safety in very low birth weight infants. Turk J Pediatr 2010;52:450-6.
59. Sagi L, Zvulunov A, Lapidoth M, et al. Effi cacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. Dermatology 2014;228:136-44.
60. Pavlakovic H, Kietz S, Lauerer P, et al. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010;126:e1589-93.
61. Moehrle M, Leaute-Labreze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013;30:245-9.
62. Ma G, Wu P, Lin X, et al. Fractional carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: a pilot study. Pediatr Dermatol 2014;31:286-91.
63. Yu L, Li S, Su B, et al. Treatment of super ficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants. Exp Ther Med 2013;6:388-90.
64. Qiu Y, Ma G, Yang J, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. Clin Exp Dermatol 2013;38:845-50.
65. Berk DR, Lehman PA, Franz TJ, et al. On topical timolol gel-forming solution for infantile hemangiomas. Pediatr Dermatol 2013;30:160-1.
66. Xue K, Hildebrand GD. Topical timolol maleate 0.5% for infantile capillary haemangioma of the eyelid. Br J Ophthalmol 2012;96:1536-7.
67. Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin Exp Dermatol 2013;38:143-6.
68. Ye XX, Jin YB, Lin XX, et al. [Topical timolol in the treatment of periocular superficial infantile hemangiomas: a prospective study]. Zhonghua Zheng Xing Wai Ke Za Zhi 2012;28:161-4.
69. Chambers CB, Katowitz WR, Katowitz JA, et al. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg 2012;28:103-6.
70. Oranje AP, Janmohamed SR, Madern GC, et al. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology 2011;223:330-4.
71. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012;29:28-31.
72. Blatt J, Morrell DS, Buck S, et al. Beta-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phila) 2011;50:757-63.
73. Vukovich RA, Foley JE, Brown B, et al . Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate). Br J Clin Pharmacol 1979; 7(Suppl 2):167S-72S.